Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy

Journal of Urology

Volumn 163, Issue 6, 2000, Pages 1743-1746

  Herr, Harry W ^a   O'Sullivan, Maryellen ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Androgens; Prostatic neoplasms; Quality of life

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; EMOTIONAL STRESS; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TERATOGENESIS;

EID: 0034114889     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67533-7     Document Type: Article

References (13)

1. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol, 79: 235, 1997
2. Wasson, J. H., Fowler, F. J., Jr. and Barry, M. J.: Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol, 159: 1993, 1998
3. Adolfsson, J., Steineck, G. and Hedlund, P. O.: Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J Urol, 161: 505, 1999
4. Kornblith, A. B., Herr, H. W., Ofman, U. S., et al: Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 73: 2791, 1994
5. Moore, M. J., Osoba, D., Murphy, K. et al: Use of palliative end points to evaluate the effects of mitoxantrone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol, 12: 689, 1994
6. Litwin, M. S., Hays, R. D., Fink, A. et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA, 273: 129, 1995
7. Herr, H. W., Kornblith, A. B. and Ofman, U.: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer, suppl., 71: 1143, 1993
8. Boccardo, F., Rubagotti, A., Barichello, M. et al: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project Study. J Clin Oncol, 17: 2027, 1999
9. Moinpour, C. M., Savage, M. J., Troxel, A. et al: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst, 90: 1537, 1998
10. Viau, V. and Meaney, M. J.: The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J Neurosci, 16: 1866, 1996
11. Morley, J. E., Kaiser, F. E., Sih, R. et al: Testosterone and frailty. Clin Geriatr Med, 13: 685, 1997
12. Roth, A. J., Kornblith, A. B., Batel-Copel, L. et al: Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer, 82: 1904, 1998
13. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3282 deaths in 5710 patients. Lancet, 346: 265, 1995